GLP-1 drugs versus bariatric surgery for treating obesity
How do the new weight-loss drugs stack up against surgery? And when might a combined approach help?
- Reviewed by Eric G. Sheu, MD, PhD, Contributor
Prescriptions for the weight-loss drugs known as GLP-1s - especially semaglutide (Wegovy) and tirzepatide (Zepbound) - have surged in recent years. Meanwhile, the number of weight-loss surgeries has declined. Known as bariatric surgery, these procedures remove or bypass part of the stomach.
To continue reading this article, you must log in.
Source matters. Subscribe to HarvardHealthOnline+ FREE for 30 days for unlimited access to the site – where all content is reviewed by an HMS physician or faculty expert.
With HHO+ you get these exclusive benefits:
- Unlimited access to all Harvard Health Online content
- 4 expertly curated newsletters delivered monthly
- Customized website experience aligned to your health goals
- In-depth health guides on topics like sleep, exercise, and more
- Interactive features like videos and quizzes
- Members-only access to exclusive articles and resources
SPECIAL OFFER! UNLOCK EXPERT ACCESS for 30 days FREE!
Already a member? Login ».
About the Author
Julie Corliss, Executive Editor, Harvard Heart Letter
About the Reviewer
Eric G. Sheu, MD, PhD, Contributor
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.